Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia

Erica Brivio,¹ Francisco Bautista¹ and C. Michel Zwaan^{1,2}

¹Princess Máxima Center for Pediatric Oncology, Utrecht and ²Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands

Correspondence: C.M. Zwaan

c.m.zwaan@prinsesmaximacentrum.nl

Received: Accepted: November 8, 2023. March 15, 2024.

https://doi.org/10.3324/haematol.2023.283815

©2024 Ferrata Storti Foundation Published under a CC BY-NC license 🖭 🔅 **Supplementary figure 1**. Flow diagram reporting the results of the search at clinicaltrials.gov.

Total studies identified (n=117)Blinatumomab (n=27)Inotuzumab (n=13)Isatuximab (n=2)Daratumumab (n=4)Moxetumumab (n=4)Epratuzumab (n=5)Ofatumumab (n=6)Rituximab (n=53)Mosunetuzumab (n=0)Glofitamab (n=0)Tagraxofup (n=1)SAR443579 (n=1)IMGN632 (n=1)	Total excluded studies for analysis (n=35): - Rituximab: * 32 studies were evaluating rituximab in the HSCT setting (other than prevention or treatment of relapse) or were addressed to patients with Burkitt lymphoma/leukemia
↓	 * 3 studies did not include rituximab within the interventions proposed
Total studies included for analysis (n=82)Blinatumomab (n=27)Inotuzumab (n=13)Isatuximab (n=2)Daratumumab (n=4)Moxetumumab (n=4)Epratuzumab (n=5)Ofatumumab (n=6)Rituximab (n=18)Tagraxofup (n=1)SAR443579 (n=1)IMGN632 (n=1)	

CART: Chimeric antigen receptor therapies; GVHD: Graft versus host disease; HSCT: Hematopoietic stem cell transplantation

Supplementary Table 1. List of all studies identified through the search at clinicaltrials.gov (see excel file)